Integra (IART) Reports Q4 Earnings: What Key Metrics Have to Say

Financial Performance - For the quarter ended December 2024, Integra LifeSciences reported revenue of $442.65 million, reflecting an 11.5% increase year-over-year [1] - EPS for the quarter was $0.97, up from $0.89 in the same quarter last year, resulting in a surprise of +14.12% compared to the consensus estimate of $0.85 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $444.66 million, with a surprise of -0.45% [1] Key Metrics - Organic revenue growth was 3.5%, exceeding the four-analyst average estimate of 2.4% [4] - Revenue from Codman Specialty Surgical totaled $314.66 million, compared to the four-analyst average estimate of $317 million, representing a year-over-year change of +15.8% [4] - Revenue from Tissue Technologies was $127.99 million, slightly above the four-analyst average estimate of $127.54 million, with a year-over-year change of +2.1% [4] - Revenue from Tissue Technologies in Wound Reconstruction and Care was $101.53 million, surpassing the estimated $95.61 million, marking an 8.2% increase year-over-year [4] - Revenue from Tissue Technologies' Private Label was $26.46 million, below the average estimate of $32.20 million, indicating a year-over-year decline of -16.2% [4] Stock Performance - Shares of Integra have returned -16.4% over the past month, contrasting with the Zacks S&P 500 composite's -1.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]